Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma

Table 3 Distribution and median survival of patients with hepatocellular carcinoma according to the studied staging systems

Staging/grading system	Stage/grade	Percentage of patients	Median survival (mo)	P-value
CTP	A	50.6	19	< 0.001
	B	36.1	11
	C	13.4	3.8
BCLC	0	3.6	25.4	< 0.001
	A	27.5	19.8
	B	26.6	16
	C	28.9	8
	D	13.4	4
TNM	I	19.5	23	< 0.001
	II	36.6	18
	III	35.4	8
	IV	8.5	6
ALBI	1	12	28.6	< 0.001
	2	63.2	14
	3	24.7	5.8
PALBI	1	10.1	34.6	< 0.001
	2	29	27.5
	3	33.9	23.9
	4	27	7.5
ALBI-based BCLC	0	1.5	Undefined	< 0.001
	A	5.9	30.8
	B	67.2	14.2
	C	2.2	11
	D	23.2	5
ALBI-T	0	2.6	42	< 0.001
	1	18.1	28.9
	2	30.4	17
	3	31.1	8
	4	16	5
	5	1.8	3
Modified ALBI-T	0	2.6	42	< 0.001
	1	9.1	28.9
	2	18.5	20
	3	27.9	14
	4	25.5	8
	5	14.6	5
	6	1.8	3

CTP: Child-Turcotte-Pugh score; ALBI: Albumin-bilirubin score; TNM: Tumor-node-metastasis staging system; BCLC: Barcelona Clinic Liver Cancer staging system.